Want to see SPRB full AI Analyst Report?
SPRB Stock Chart & Stats
$70.30
--
Market closed
$70.30
--
Day’s Range― - ―
52-Week Range$6.77 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)78.79K
Market Cap
$119.83M
Enterprise Value$42.71
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$7.12M
Price to Earnings (P/E)―
Beta-9.89
Next Earnings
Aug 17, 2026EPS Estimate
-5.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-37.60
Shares Outstanding2,752,278
10 Day Avg. Volume73,049
30 Day Avg. Volume78,793
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$151.00Price Target Upside114.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-25.18
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt relative to equity reduces near-term solvency and interest burden, giving management durable financial flexibility. For a clinical-stage biotech, limited leverage lowers refinancing pressure and supports continuity of trials and operations over the next several months.
Recent Equity FinancingThe ~$69M equity raise (including exercised option) materially strengthens liquidity and extends runway, reducing near-term fundraising urgency. This financing directly supports ongoing late-stage program execution and makes meeting upcoming clinical and regulatory milestones more achievable.
Focused Clinical PipelineA concentrated pipeline centered on tildacerfont provides clear strategic focus and resource allocation for a specialized endocrine indication. This focus can accelerate trial design, regulatory strategy, and expert hiring, making clinical outcomes meaningful drivers of long-term company value.
Bears Say
No Recent Revenue & Cash BurnZero recent revenue combined with persistent negative operating and free cash flow (~-$29.3M TTM) means the company depends on capital markets to fund operations. Continued cash burn raises structural execution risk for multi-month clinical programs absent additional financing or a material shift to positive cash generation.
Reliance On External Funding / DilutionThe recent equity raise and referenced loan facility highlight ongoing dependence on external capital. Dilution and the termination of the Kaken collaboration remove potential milestone/royalty upside, meaning future program funding and value realization remain contingent on further financings or development success.
Erosion Of Shareholder Equity / Negative ROEMaterial equity erosion and a negative TTM ROE reflect sustained losses and dilution over multiple years. This structural weakness signals that, without clinical or commercial inflection points, shareholder returns are challenged and recovery of equity value may require successful regulatory outcomes or strategic transactions.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences, Inc.’s price range in the past 12 months?
Spruce Biosciences, Inc. lowest stock price was $6.77 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences, Inc.’s market cap?
Spruce Biosciences, Inc.’s market cap is $119.83M.
When is Spruce Biosciences, Inc.’s upcoming earnings report date?
Spruce Biosciences, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Spruce Biosciences, Inc.’s earnings last quarter?
Spruce Biosciences, Inc. released its earnings results on May 13, 2026. The company reported -$8.94 earnings per share for the quarter, missing the consensus estimate of -$7.934 by -$1.006.
Is Spruce Biosciences, Inc. overvalued?
According to Wall Street analysts Spruce Biosciences, Inc.’s price is currently Undervalued.
Does Spruce Biosciences, Inc. pay dividends?
Spruce Biosciences, Inc. does not currently pay dividends.
What is Spruce Biosciences, Inc.’s EPS estimate?
Spruce Biosciences, Inc.’s EPS estimate is -5.79.
How many shares outstanding does Spruce Biosciences, Inc. have?
Spruce Biosciences, Inc. has 2,752,278 shares outstanding.
What happened to Spruce Biosciences, Inc.’s price movement after its last earnings report?
Spruce Biosciences, Inc. reported an EPS of -$8.94 in its last earnings report, missing expectations of -$7.934. Following the earnings report the stock price went up 1.562%.
Which hedge fund is a major shareholder of Spruce Biosciences, Inc.?
Currently, no hedge funds are holding shares in SPRB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spruce Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$151.00 (114.79% Upside)
$151.00 (114.79% Upside)
Blogger Sentiment
Bullish
SPRB Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
511.08%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.47%
Trailing 12-Months
Company Description
Spruce Biosciences, Inc.
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
SPRB Stock 12 Month Forecast
Average Price Target
$151.00
▲(114.79% Upside)
Technical Analysis
Ownership Overview
66.21% Insiders
1.04% Mutual Funds
12.90% Other Institutional Investors
11.42% Public Companies and
Individual Investors